<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821753</url>
  </required_header>
  <id_info>
    <org_study_id>K170406J</org_study_id>
    <nct_id>NCT03821753</nct_id>
  </id_info>
  <brief_title>The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes</brief_title>
  <acronym>REVADIAB</acronym>
  <official_title>The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Délégation de la Recherche Clinique et de l'innovation (DRCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRC (Centre de Recherche Clinique)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SFD (Société Francophone du Diabète)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Revadiab is case-control study aimed to demonstrate that retinal capillary density is altered&#xD;
      in patients with type 1 diabetes with glycemic variability compared to those with comparable&#xD;
      glycemic control without glycemic variability. An OCT angiography will be used to precisely&#xD;
      evaluate retinal capillary density.&#xD;
&#xD;
      A secondary objective will be to evaluate if glycemic variability is associated with&#xD;
      cognitive dysfunction, using a neuro psychologic evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HbA1c doesn't explain all the microvascular complications of diabetes, especially&#xD;
      microvascular complications. Glycemic variability is associated with increased oxidative&#xD;
      stress, free radicals and endothelial dysfunction; it contributes to the pathogenesis of&#xD;
      diabetic complications.&#xD;
&#xD;
      The relationship between glycemic variability and microangiopathic complications especially&#xD;
      retinal but also neurological, needs to be studied.&#xD;
&#xD;
      The principal objective of Revadiab study is to demonstrate a correlation between glycemic&#xD;
      variability and macular retinal microcirculation in patient with type 1 diabetes.&#xD;
&#xD;
      The secondary objective is to search a correlation between glycemic variability and :&#xD;
&#xD;
        -  Alteration of cognitive functions.&#xD;
&#xD;
        -  Severity of peripheral diabetic retinopathy and retinal neuronal damage.&#xD;
&#xD;
        -  Other micro and macro angiopathic complications.&#xD;
&#xD;
        -  Oxidative stress and inflammation.&#xD;
&#xD;
      Two groups of type 1 diabetic patients will be compared:&#xD;
&#xD;
        -  Case: Patient with significant glycemic variability.&#xD;
&#xD;
        -  Control: Patients without glycemic variability.&#xD;
&#xD;
      The severity of diabetic retinopathy will be evaluated by the degree of occlusion of small&#xD;
      vessels in the central retinal region as measured by OCT angiography.&#xD;
&#xD;
      Acts or Product necessary to research :&#xD;
&#xD;
        -  Non-invasive retinal imaging (OCT and OCT- Angiography, retinophotography)&#xD;
&#xD;
        -  Neuropsychological tests.&#xD;
&#xD;
        -  Blood test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Macular capillary density in the external deep capillary network</measure>
    <time_frame>3 months</time_frame>
    <description>Macular capillary density in the external deep capillary network measured by OCT-Angiography (no later than 3 months after inclusion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular capillary density in the deep capillary and deep capillary network</measure>
    <time_frame>3 months</time_frame>
    <description>Macular capillary density in the deep capillary and deep capillary network measured by OCT-angiography (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of the central avascular zone</measure>
    <time_frame>3 months</time_frame>
    <description>Area of the central avascular zone by OCT-Angiography (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular edema presence</measure>
    <time_frame>3 months</time_frame>
    <description>Macular edema presence by OCT (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Layer thickness reduction of the ganglion cells</measure>
    <time_frame>3 months</time_frame>
    <description>Layer thickness reduction of the ganglion cells measured by OCT (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy stage</measure>
    <time_frame>3 months</time_frame>
    <description>Diabetic retinopathy stage evaluated with retinographies (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of pre-retinal neovascular vessels and/or pre-papillary</measure>
    <time_frame>3 months</time_frame>
    <description>Development of pre-retinal neovascular vessels and/or pre-papillary (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of neovascular complications</measure>
    <time_frame>3 months</time_frame>
    <description>Occurrence of neovascular complications: vitreous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemorrhage, retina tractional detachment, neovascular glaucoma</measure>
    <time_frame>3 months</time_frame>
    <description>Haemorrhage, retina tractional detachment, neovascular glaucoma (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Renal function evaluation: microalbuminuria and creatinine determination (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of peripheral neuropathy</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of peripheral neuropathy : monofilament test (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic cardiopathy</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement method: treatment with angioplasty or coronary artery bypass graft, Assessment of vascular risk by measuring the coronal calcium score, and determination of BNP and troponin. (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Number of severe hypoglycemia since 1 year, threshold for hypoglycemia no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>characterization of circulating inflammatory and endothelial cells and CRP-US assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers</measure>
    <time_frame>3 months</time_frame>
    <description>Oxidative stress markers: Measurements of 8-iso-prostaglandin F2 alpha urinary and 1,5-anhydroglucitol sanguine. (no later than 3 months after inclusion)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Microvascular Complications</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetes</condition>
  <condition>Microangiopathy</condition>
  <condition>Angiography</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Patients with glycemic variability, defined by a coefficient of variation (CV)&gt; 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Case</intervention_name>
    <description>OCT&#xD;
OCT-Angiography,&#xD;
Retinophotography&#xD;
Neuropsychological tests</description>
    <arm_group_label>Case</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>OCT&#xD;
OCT-Angiography,&#xD;
Retinophotography&#xD;
Neuropsychological tests</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion of adult patients with T1D with more than 10 years of diabetes and users of the&#xD;
        FreeStyle Free continuous measurement system.&#xD;
&#xD;
        Case: Patients with glycemic variability, defined by a coefficient of variation (CV) &gt; 36%,&#xD;
        calculated from continuous glucose measurements data by Free Style Libre® (Abbott).&#xD;
&#xD;
        Controls: Patients without glycemic variability, defined by a coefficient of variation (CV)&#xD;
        ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for&#xD;
        HbA1c (+/- 0.5%).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years&#xD;
&#xD;
          -  Type 1 diabetes (T1D)&#xD;
&#xD;
          -  Using Free FreeStyle&#xD;
&#xD;
          -  Diabete evolving for 10 years or more&#xD;
&#xD;
          -  Case: Patients with glycemic variability, defined by a coefficient of variation (CV) &gt;&#xD;
             36%, calculated from continuous glucose measurements data by Free Style Libre®&#xD;
             (Abbott)&#xD;
&#xD;
          -  Controls: Patients without glycemic variability, defined by a coefficient of variation&#xD;
             (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case&#xD;
             group for HbA1c (+/- 0.5%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetic patient&#xD;
&#xD;
          -  Corticotherapy&#xD;
&#xD;
          -  Comorbidity like cancer&#xD;
&#xD;
          -  Antecedent of vitreoretinal pathology&#xD;
&#xD;
          -  Antecedent of vitreoretinal surgery&#xD;
&#xD;
          -  Important cataract, with an important opacity that prevents a reliable evaluation of&#xD;
             capillary density in OCT angio&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Pierre RIVELINE, Professor</last_name>
    <phone>+33(0) 1 49 95 83 79</phone>
    <email>jeanpierre.riveline@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre RIVELINE, Professor</last_name>
      <phone>+33(0) 1 49 95 83 79</phone>
      <email>jeanpierre.riveline@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Glycemic variability</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Macular retinal microcirculation</keyword>
  <keyword>Microangiopathy</keyword>
  <keyword>Cognitive dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

